JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Cell lines
human corneal epithelial cells(HCE)
Preparation method
Soluble in DMSO > 10.75 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.
Reacting condition
5 μM of FITC(Fluorescein isothiocyanate) labelled natamycin for 1 h at 37°C
Applications
The drug natamycin had a broad spectrum activity against filamentous fungi in the HCE, therefore, it was considered as the drug of choice for the treatment of filamentous fungi associated Keratitis.
Disease models
Patients with smear positive or culture-positive filamentous fungal corneal ulcers
Dosage form
5% natamycin plus 0.02% preservative, one drop to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until 3 weeks
Application
Topical natamycin was superior to topical voriconazole for the treatment of filamentous fungal corneal ulcers, and in particular those culture-positive for Fusarium species. Vision-related functioning was higher among those treated with natamycin compared with voriconazole.
Other notes
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
References:
[1]. Jain A1, Shah SG, Chugh A, Cell penetrating peptides as efficient nanocarriers for delivery of antifungal compound, natamycin for the treatment of fungal keratitis. Pharm Res. 2015 Jun;32(6):1920-30. doi: 10.1007/s11095-014-1586-x. Epub 2014 Dec 3.
[2]. Rose-Nussbaumer J1,2,3, Prajna NV4, et al, Risk factors for low vision related functioning in the Mycotic Ulcer Treatment Trial: a randomised trial comparing natamycin with voriconazole. Br J Ophthalmol. 2016 Jul;100(7):929-932. doi: 10.1136/bjophthalmol-2015-306828. Epub 2015 Nov 3.
